Skip to main content

Table 1 Characteristics of included studies

From: The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Authors (Ref)Publication yearSample size (control/intervention)Population/CountryIntervention (name and daily dose)DurationPresented dataAge (y) (control, intervention)
Arzola-Paniagua (a) et al. [18]201624/15Obesity/MexicoResveratrlol 300 mg24 weeksTG33.7 ± 11.9, 38.8 ± 9.59
Arzola-Paniagua (b) et al. [18]201621/24Obesity/MexicoResveratrlol 300 mg24 weeksTG40.96 ± 10.0, 39.76 ± 8.91
Bashmakov YK et al. [19]201410/14T2DM/EgyptResveratrol 100 mg2 monthsHDL-C, LDL-C, and TC54 ± 10.1, 59.8 ± 6.6
Bhatt JK et al. [20]201229/28T2DM/IndiaResveratrol 250 mg3 monthsTG, HDL-C, LDL-C, and TC56.67 ± 8.91, 57.75 ± 8.71
Goh KP et al. [21]20145/5T2DM/SingaporeResveratrol 3000 mg12 weeksTG, HDL-C, LDL-C, and ALT55.8 ± 7.3, 56.8 ± 5.3
Imamura H et al. [22]201725/25T2DM/JapanResveratrol 100 mg12 weeksTG, HDL-C, TC57.4 ± 10.6, 58.2 ± 10.1
Zare Javid A et al. [23]201722/21T2DM/IranResveratrol 480 mg4 weeksTG49.1 ± 7.4, 50.9 ± 8.9
Kjær TN et al. [24] (a)201712/21MetS/DenmarkResveratrol 150 mg16 weeksTG, HDL-C, LDL-C, TC, and ALT49.1 ± 6.69, 47.8 ± 6.36
Kjær TN et al. [24] (b)201712/21MetS/DenmarkResveratrol 1000 mg16 weeksTG, HDL-C, LDL-C, TC, and ALT51.9 ± 5.86, 47.8 ± 6.36
Kumar BJ et al. [25]201329/28T2DM/IndiaResveratrol 250 mg6 monthsTG, HDL-C, LDL-C, and TC56.67 ± 8.91, 57.75 ± 8.71
Militaru C et al. [26] (a)201329/29Stable angina/RomaniaResveratrol 20 mg2 monthsTG, HDL-C, LDL-C, and TC64.9 ± 5.8, 64.2 ± 7.1
Militaru C et al. [26] (b)201329/29Stable angina/RomaniaResveratrol 20 mg2 monthsTG, HDL-C, LDL-C, and TC66.3 ± 5.5, 63.7 ± 6.2
Most J et al. [27]201620/18Obese/NetherlandsResveratrol 80 mg + 282 mg epigallocatechin-3-gallate12 weeksTG, HDL-C, LDL-C, and TC36.1 ± 9.33, 38.7 ± 9.83
Movahed A et al. [28]201331/33T2DM/IranResveratrol 1000 mg45 daysTG, HDL-C, LDL-C, TC, ALT,AST, and GGT52.45 ± 6.18, 51.81 ± 6.99
Poulsen MM et al. [29]201312/12Obese/ DenmarkResveratrol 1500 mg4 weeksTG, HDL-C, LDL-C, TC, and ALT44.7 ± 12.12, 31.9 ± 10.03
Seyyedebrahimi S et al. [30]201823/23T2DM/ IranResveratrol 800 mg2 monthsTG, HDL-C, LDL-C, TC, ALT, and AST54.96 ± 6.37, 58.72 ± 6.06
Méndez-del Villar M et al. [31]201410/11MetS/ MexicoResveratrol 1500 mg3 monthsTG, HDL-C, LDL-C, and TC39.8 ± 5.4, 40.3 ± 5.4
Witte AV et al. [32]201423/23Overweight subjects/GermanyResveratrol 200 mg26 weeksTG and TC64.8 ± 6.8, 63.7 ± 5.3
Chachay VS et al. [33]201410/10NAFLD/AustraliaResveratrol 3000 mg8 weeksTG, HDL-C, LDL-C, TC, ALT, and AST48.8 ± 12.2, 47.5 ± 11.2
Chen S et al. [34]201530/30NAFLD/ChinaResveratrol 300 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT45.2 ± 10.0, 43.5 ± 11.0
Faghihzadeh F et al. [35]201525/25NAFLD/IranResveratrol 500 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT44.04 ± 10.10, 46.28 ± 9.52
Kantartzis K et al. [36]201852/53Overweight and insulin resistant Subjects/GermanyResveratrol 150 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT18–70
Most J et al. [37]201814/11Obesity/NetherlandsResveratrol 80 mg + 282 mg epigallocatechin-3-gallate12 weeksTG36 ± 3, 40 ± 3
Khodabandehloo H et al. [38]201820/25T2DM/IranResveratrol 800 mg/day8 weeksTG, HDL-C, LDL-C, TC, ALT, and AST56.48 ± 6.72, 61.10 ± 5.61
Chekalina NL et al. [39]201633/30CAD/UkraineResveratrol 100 mg2 monthsTG, HDL-C, LDL-C, and TC48–72
Fujitaka K et al. [40]201117/17MetS/JapanTrans resveratrol 100 mg (Longevinex)3 monthsTG, HDL-C, and LDL-C63 ± 9,
62 ± 14
Cicero AF et al. [41]20160verall 25Hypercholesterolemic/ItalyResveratrol 20 mg and monacolins from M. purpureus 10 mg4 weeksTG, HDL-C, LDL-C, TC, ALT, and AST18–70
Biesinger S et al. [42]2016Overall 18Hypertension/USAResveratrol 60 mg4 weeksTG, HDL-C, LDL-C, and TC44 ± 3
Timmers S et al. [43]2011Overall 11Obesity/NetherlandsResveratrol 150 mg30 daysTG52.5 ± 6.95, 52.5 ± 6.95
van der Made SM et al. [44]2015Overall 45Obesity/NetherlandsResveratrol 150 mg4 weeksHDL-C and TC61 ± 7
de light M et al. [45]2018Overall 13T2DM/NetherlandsResveratrol 150 mg30 daysHDL-C, LDL-C, TC, AST, and GGT66 ± 7.7
Simental-Mendía LE et al. [46]201931/31Dyslipidemia/MéxicoResveratrol 100 mg8 weeksTG, HDL-C, LDL-C, and TC20–65
Fodor K et al. [47](a)201846/81Stroke/RomaniaResveratrol 100 mg + Allopathic treatment + physical rehabilitation48 weeksTG, HDL-C, LDL-C, and TC65.03 ± 8.24, 64.78 ± 6.32
Fodor K et al. [47](b)201846/55Stroke/RomaniaResveratrol 200 mg + Allopathic treatment + physical rehabilitation48 weeksTG, HDL-C, LDL-C, and TC64.52 ± 8.05, 64.78 ± 6.32
Mazza A et al. [48]201830/30Hypertensive and hypercholesterolemic subjects/ItalyNutraceutical compounds capsule containing resveratrol 20 mg + standardized Mediterranean diet4 weeksTG, HDL-C, LDL-C, TC, ALT, and AST51.5 ± 7.8, 53.0 ± 8.1
  1. CAD Coronary artery disease, MetS Metabolic syndrome, NAFLD Non-alcoholic fatty liver disease, NR Not reported, T2DM Type 2 diabetes mellitus, LDL-C Low-density lipoprotein-cholesterol, HDL-C High-density lipoprotein-cholesterol, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase